$7.12
-0.02-0.28%
Last update: Jul 19, 7:57 PM
15 minutes delayed
Comments
Loading...
BioCryst Pharma
BCRXNASDAQ
BioCryst Pharma (NASDAQ:BCRX) Stock, Insider Trading Activity
BioCryst Pharma: Insider buying and selling updated today.
What is Insider Activity?
Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock. Insiders' buy and sell transactions provide valuable insights into their confidence in the company's future performance.
What are BioCryst Pharmaceuticals Inc Insiders Doing?
At BioCryst Pharmaceuticals Inc, recent insider activity has drawn attention. Over the last 30 days, insiders have reported selling a total of 8.60K shares worth $54.35K, meanwhile, insiders have report no purchases in the last 30 days.
Notable Recent Insider Buys and Sales
- On May 15, 2024, Anthony Doyle, the company's CHIEF FINANCIAL OFFICER purchased 36.3K shares for $5.57 each.
- On May 15, 2024, Helen Thackray, the company's CHIEF R&D OFFICER purchased 30K shares for $5.86 each.
- On May 15, 2024, Jon Stonehouse, the company's PRESIDENT & CEO purchased 30K shares for $5.55 each.
Ownership Statistics for BioCryst Pharmaceuticals Inc
Institutional Shares Held
87.825M
Institutional Percentage Held
42.6%
| Jun 25, 2024 | Amy McKee | DIRECTOR | -8.60K | $6.32 | -$54.35K | SELL | -23.61% | 27.83K | Jun 24 | View |
| Jun 17, 2024 | MACHELLE SANDERS | DIRECTOR | -4.69K | $6.00 | -$28.13K | SELL | -14.46% | 27.74K | Jun 17 | View |
| Jun 14, 2024 | THERESA HEGGIE | DIRECTOR | 122.00 | $6.11 | -$40.92K | GRANT | 0.23% | 52.85K | Jun 12 - Jun 14 | View |
| May 31, 2024 | ALAN LEVIN | DIRECTOR | 7.86K | $6.36 | $50.00K | BUY | 21.19% | 44.95K | May 30 | View |
| May 29, 2024 | STEVE ASELAGE | DIRECTOR | 2.50K | $6.40 | $16.00K | BUY | 3.95% | 65.84K | May 24 | View |
| May 22, 2024 | Nancy Hutson | DIRECTOR | 5.00K | $6.38 | $31.90K | BUY | 6.11% | 86.82K | May 20 | View |
| May 22, 2024 | VINCENT MILANO | DIRECTOR | 15.00K | $6.25 | $93.75K | BUY | 28.85% | 67.00K | May 20 | View |
| May 15, 2024 | Anthony Doyle | CHIEF FINANCIAL OFFICER | 36.30K | $5.57 | $202.19K | BUY | 15.75% | 266.74K | May 14 | View |
| May 15, 2024 | Helen Thackray | CHIEF R&D OFFICER | 30.00K | $5.86 | $175.80K | BUY | 12.39% | 272.14K | May 14 | View |
| May 15, 2024 | Steven Galson | DIRECTOR | 21.94K | $5.49 | $120.45K | BUY | 74.09% | 51.55K | May 13 | View |
| May 15, 2024 | Alane P Barnes | CHIEF LEGAL OFFICER | 5.00K | $5.53 | $27.65K | BUY | 1.69% | 300.76K | May 13 | View |
| May 15, 2024 | Jon Stonehouse | PRESIDENT & CEO | 30.00K | $5.55 | $166.50K | BUY | 2.68% | 1.15M | May 13 | View |
| May 15, 2024 | Charles Gayer | CHIEF COMMERCIAL OFFICER | 30.00K | $5.47 | $164.10K | BUY | 10.81% | 307.53K | May 13 | View |
| Jun 15, 2023 | MACHELLE SANDERS | DIRECTOR | 12.74K | $7.98 | -$31.92K | GRANT | 99.06% | 25.61K | Jun 13 - Jun 15 | View |
| Jun 15, 2023 | Nancy Hutson | DIRECTOR | 3.88K | $8.04 | -$103.44K | GRANT | 4.98% | 81.82K | Jun 13 - Jun 14 | View |
| Apr 05, 2023 | Helen Thackray | CHIEF R&D OFFICER | -7.00K | $8.29 | -$58.03K | SELL | -3.27% | 207.28K | Apr 03 | View |
| Feb 02, 2023 | Jon Stonehouse | PRESIDENT & CEO | 0.00 | $7.92 | -$493.00K | SELL-OPTIONS | 0.00% | 1.01M | Dec 29 - Feb 01 | View |
| Dec 19, 2022 | Jon Stonehouse | PRESIDENT & CEO | -14.10K | $10.90 | -$153.69K | SELL | -1.55% | 892.73K | Dec 15 | View |
| Dec 19, 2022 | Helen Thackray | CHIEF R&D OFFICER | -3.13K | $10.89 | -$34.03K | SELL | -2.29% | 133.28K | Dec 15 | View |
| Dec 19, 2022 | Anthony Doyle | CHIEF FINANCIAL OFFICER | -5.70K | $10.90 | -$62.13K | SELL | -3.36% | 163.97K | Dec 15 | View |
| Dec 19, 2022 | Charles Gayer | CHIEF COMMERCIAL OFFICER | -6.10K | $10.90 | -$66.49K | SELL | -2.80% | 211.61K | Dec 15 | View |
| Dec 19, 2022 | Michael Jones | EXEC. DIRECTOR, FINANCE - PAO | -445.00 | $10.90 | -$4.85K | SELL | -3.97% | 10.75K | Dec 15 | View |
| Dec 19, 2022 | Alane P Barnes | CHIEF LEGAL OFFICER | -4.17K | $10.88 | -$45.42K | SELL | -2.06% | 198.77K | Dec 15 | View |
| Dec 02, 2022 | Michael Jones | EXEC. DIRECTOR, FINANCE - PAO | 0.00 | $7.21 | -$99.67K | SELL-OPTIONS | 0.00% | 11.20K | Dec 01 | View |
| Dec 02, 2022 | Jon Stonehouse | PRESIDENT & CEO | 0.00 | $7.18 | -$3.43M | SELL-OPTIONS | 0.00% | 906.83K | Dec 01 - Dec 02 | View |
| Nov 16, 2022 | Yarlagadda Babu | CHIEF DISCOVERY OFFICER | 68.48K | $7.65 | -$295.43K | SELL-OPTIONS | 29.77% | 298.54K | Nov 14 | View |
| Apr 20, 2022 | GEORGE ABERCROMBIE | DIRECTOR | 0.00 | $7.18 | -$38.60K | SELL-OPTIONS | 0.00% | 0.00 | Apr 18 | View |
| Apr 04, 2022 | Helen Thackray | CHIEF R&D OFFICER | -7.60K | $16.20 | -$123.12K | SELL | -5.28% | 136.40K | Apr 01 | View |
| Mar 14, 2022 | William Sheridan | CHIEF MEDICAL OFFICER | -12.84K | $10.05 | -$2.24M | SELL | -25.27% | 37.95K | Mar 10 | View |
| Mar 09, 2022 | Yarlagadda Babu | CHIEF DISCOVERY OFFICER | -20.00K | $17.16 | -$343.20K | SELL | -8.00% | 230.06K | Mar 07 | View |
| Mar 03, 2022 | Michael L Jones | EXEC. DIRECTOR, FINANCE - PAO | 0.00 | $10.96 | -$28.68K | SELL-OPTIONS | 0.00% | 11.20K | Mar 01 | View |
| Feb 16, 2022 | GEORGE ABERCROMBIE | DIRECTOR | 0.00 | $10.91 | -$75.90K | SELL-OPTIONS | 0.00% | 0.00 | Feb 15 | View |
| Jan 13, 2022 | Jon Stonehouse | PRESIDENT & CEO | 0.00 | $9.88 | -$1.90M | SELL-OPTIONS | 0.00% | 906.60K | Jan 11 | View |
| Dec 09, 2021 | Yarlagadda Babu | CHIEF DISCOVERY OFFICER | 31.90K | $8.46 | -$73.96K | SELL-OPTIONS | 17.42% | 215.06K | Dec 07 | View |
| Nov 24, 2021 | VINCENT MILANO | DIRECTOR | 7.50K | $12.19 | $91.42K | BUY | 75.00% | 17.50K | Nov 24 | View |
| Nov 24, 2021 | Anthony Doyle | CHIEF FINANCIAL OFFICER | 35.26K | $12.48 | $440.02K | BUY | 60.31% | 93.72K | Nov 23 | View |
| Nov 17, 2021 | GEORGE ABERCROMBIE | DIRECTOR | 0.00 | $7.79 | -$44.75K | SELL-OPTIONS | 0.00% | 0.00 | Nov 15 | View |
| Oct 19, 2021 | Nancy Hutson | DIRECTOR | 0.00 | $9.43 | -$1.25M | SELL-OPTIONS | 0.00% | 65.07K | Oct 15 | View |
| Sep 17, 2021 | GEORGE ABERCROMBIE | DIRECTOR | 0.00 | $8.85 | -$62.15K | SELL-OPTIONS | 0.00% | 0.00 | Sep 15 | View |
| Sep 15, 2021 | KENNETH LEE JR | DIRECTOR | 9.00K | $9.29 | -$43.80K | SELL-OPTIONS | 59.01% | 24.25K | Sep 13 | View |
| Sep 14, 2021 | GEORGE ABERCROMBIE | DIRECTOR | -3.00K | $8.97 | -$913.95K | SELL | -100.00% | 0.00 | Sep 10 | View |
| Jul 19, 2021 | GEORGE ABERCROMBIE | DIRECTOR | 0.00 | $9.16 | -$65.30K | SELL-OPTIONS | 0.00% | 3.00K | Jul 15 | View |
| Jun 14, 2021 | Nancy Hutson | DIRECTOR | 0.00 | $10.01 | -$319.85K | SELL-OPTIONS | 0.00% | 65.07K | Jun 10 | View |
| Jun 01, 2021 | William Sheridan | CHIEF MEDICAL OFFICER | 0.00 | $10.17 | -$1.58M | SELL-OPTIONS | 0.00% | 14.47K | May 27 - May 28 | View |
| May 26, 2021 | GEORGE ABERCROMBIE | DIRECTOR | 0.00 | $8.27 | -$75.14K | SELL-OPTIONS | 0.00% | 3.00K | May 24 | View |
| May 13, 2021 | Alane P Barnes | CHIEF LEGAL OFFICER | 35.85K | $8.17 | -$642.45K | SELL-OPTIONS | 32.51% | 146.13K | May 11 - May 12 | View |
| May 12, 2021 | GEORGE ABERCROMBIE | DIRECTOR | -7.00K | $12.70 | -$88.90K | SELL | -70.00% | 3.00K | May 10 | View |
| Feb 24, 2021 | William Sheridan | SENIOR VP - CMO | 0.00 | $7.86 | -$306.07K | SELL-OPTIONS | 0.00% | 11.47K | Feb 22 | View |
| Dec 17, 2020 | Jon Stonehouse | — | 0.00 | $6.24 | -$559.94K | OPTION EXERCISE | 0.00% | 784.09K | Dec 15 | View |
| Dec 15, 2020 | Alane P Barnes | — | 0.00 | $6.05 | -$52.35K | OPTION EXERCISE | 0.00% | 108.06K | Dec 11 | View |
| Dec 08, 2020 | Alane P Barnes | — | 0.00 | $5.19 | -$28.58K | OPTION EXERCISE | 0.00% | 108.06K | Dec 04 | View |
| Aug 12, 2020 | Anthony Doyle | — | 54.00K | $4.08 | $220.32K | PURCHASE | ∞ | 54.00K | Aug 11 | View |
| Nov 18, 2019 | Jon Stonehouse | PRESIDENT & CEO | 50.00K | $1.45 | $72.50K | BUY | 6.87% | 778.09K | Nov 18 | View |
| Nov 18, 2019 | Megan Sniecinski | CHIEF BUSINESS OFFICER | 45.00K | $1.45 | $65.25K | BUY | ∞ | 45.00K | Nov 18 | View |
| Nov 18, 2019 | KENNETH LEE JR | DIRECTOR | 5.00K | $1.45 | $7.25K | BUY | 48.77% | 15.25K | Nov 18 | View |
| Nov 18, 2019 | ALEXANDER ROBERT INGRAM | DIRECTOR | 20.00K | $1.45 | $29.00K | BUY | 71.20% | 48.09K | Nov 18 | View |
| Nov 18, 2019 | Nancy Hutson | DIRECTOR | 10.00K | $1.45 | $14.50K | BUY | 23.23% | 53.05K | Nov 18 | View |
| Nov 18, 2019 | THERESA HEGGIE | DIRECTOR | 5.00K | $1.45 | $7.25K | BUY | 299.04% | 6.67K | Nov 18 | View |
| Nov 18, 2019 | Alane P Barnes | SENIOR VP, CHIEF LEGAL OFFICER | 20.00K | $1.45 | $29.00K | BUY | 24.37% | 102.06K | Nov 18 | View |
| Nov 18, 2019 | Yarlagadda Babu | SENIOR VP - DRUG DISCOVERY | 25.00K | $1.45 | $36.25K | BUY | 19.14% | 155.59K | Nov 18 | View |
| Nov 18, 2019 | STEVE ASELAGE | DIRECTOR | 15.00K | $1.45 | $21.75K | BUY | 224.82% | 21.67K | Nov 18 | View |
FAQ
Is insider trading legal?
Insider trading is legal so long as the insiders report those trades to the SEC. Illegal securities trading occurs when the insider is violating a fiduciary duty or fails to report their trades.
What are some examples of market manipulation?
Insider trading, pump and dump schemes, front running and wash trades are all examples of market manipulation. Investors who track insider asset movement should think carefully about why these insiders are trading their stocks before moving forward.
Browse insider trades on all stocks.